Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look”

ImmunityBio, Inc. (NASDAQ:IBRX) was among Jim Cramer’s recent stock calls on Mad Money. Answering a caller’s query about the stock during the recent lightning round, Cramer said:

You know there’s a lot of dispute about what they did. And I’m going to tell you that it is not clear exactly what they did wrong, but they got in trouble… I got to see how they get out of trouble, and then we’ll take a hard look at it.

ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers. A caller mentioned their small position in the stock and inquired about it during the March 27 episode. The Mad Money host replied:

Okay, that is a pure spec…. I would encourage you to own it, provided you don’t own any other spec, because that company is losing a lot of money.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.